Real-time morphology analysis for lesion assessment

Information

  • Patent Grant
  • 9743854
  • Patent Number
    9,743,854
  • Date Filed
    Friday, December 18, 2015
    8 years ago
  • Date Issued
    Tuesday, August 29, 2017
    7 years ago
Abstract
Electrodes are used to measure an electrical signal (e.g., an electrogram). One or more filters are applied to the electrical signal to generate one or more filtered signals. Features of the filtered signals are evaluated to assess a sharpness corresponding to the electrical signal. Based on the sharpness, various characteristics of a morphology of the electrogram may be evaluated over a time period.
Description
TECHNICAL FIELD

The present disclosure relates to therapies for cardiac conditions. More particularly, the present disclosure relates to methods and systems for ablation of cardiac tissue for treating cardiac arrhythmias.


BACKGROUND

Aberrant conductive pathways disrupt the normal path of the heart's electrical impulses. The aberrant conductive pathways can create abnormal, irregular, and sometimes life-threatening heart rhythms called arrhythmias. Ablation is one way of treating arrhythmias and restoring normal conduction. The aberrant pathways, and/or their sources, may be located or mapped using mapping electrodes situated in a desired location. After mapping, the physician may ablate the aberrant tissue. In radio frequency (RF) ablation, RF energy may be directed from the ablation electrode through tissue to another electrode to ablate the tissue and form a lesion.


SUMMARY

Embodiments of the present invention facilitate real-time electrogram morphology analysis. Electrodes are used to measure an electrical signal (e.g., an electrogram), which may be, for example, a unipolar signal, a bipolar signal, and/or the like. In embodiments, an “electrical signal” may be, refer to, and/or include a signal detected by a single electrode (e.g., a unipolar signal), a signal detected by two or more electrodes (e.g., a bipolar signal), a plurality of signals detected by one or more electrodes, and/or the like. One or more filters are applied to the electrical signal to generate one or more filtered signals. Features of the filtered signals are evaluated to assess a sharpness corresponding to the electrical signal. Based on the sharpness, various characteristics of a morphology of the electrogram may be evaluated over a time period.


In Example 1, a system comprises a catheter that includes a flexible catheter body having a distal portion and at least one electrode disposed on the distal portion, the at least one electrode configured to measure an electrical signal based on a cardiac activation signal. The system also includes a mapping processor configured to acquire the electrical signal from the at least one electrode, generate an electrogram based on the electrical signal, determine a sharpness associated with the electrogram, and/or determine, based on the sharpness, a characteristic of a morphology of the electrogram.


In Example 2, the system of Example 1, further comprising a display device configured to display an indication associated with at least one of the sharpness and the characteristic of the morphology of the electrogram, wherein the characteristic of the morphology of the electrogram comprises a feature related to the sharpness; and an output component configured to provide an output to the display device, wherein the output comprises the sharpness and/or the determined feature.


In Example 3, the system of any of Examples 1 and 2, wherein the catheter comprises an ablation catheter including a tissue ablation electrode configured to apply ablation energy to tissue, the system further comprising a radiofrequency (RF) generator operatively coupled to the tissue ablation electrode, wherein the RF generator is configured to generate the ablation energy and convey the generated ablation energy to the tissue ablation electrode.


In Example 4, the system of Example 3, wherein the mapping processor is configured to determine the sharpness before an ablation, during an ablation, and/or after an ablation.


In Example 5, the system of any of Examples 2-4, wherein the mapping processor comprises: a filter configured to filter the electrical signal to generate a filtered signal; and a feature detector configured to determine an amplitude of the filtered signal, wherein the determined feature comprises the determined amplitude of the filtered signal, wherein the display device is configured to indicate a relative change in the amplitude of the filtered signal during a period of time.


In Example 6, the system of Example 5, wherein the amplitude comprises at least one of an absolute amplitude, a root-mean-squared (RMS) measurement, a peak-to-peak measurement, a maximum of a peak-to-peak measurement over a window, a percentile range measurement, a beat-gated measurement, and a free-running measurement.


In Example 7, the system of any of Examples 5 and 6, wherein the filter is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.


In Example 8, the system of any of Examples 5-7, wherein the filtered signal comprises an approximate derivative of the electrical signal.


In Example 9, the system of any of Examples 5-8, wherein the filter includes a nonlinear processing element configured to attenuate one or more components of the electrical signal based on a polarity of a deflection of the electrical signal.


In Example 10, the system of Example 9, wherein the filter comprises a half-wave rectifier.


In Example 11, the system of any of Examples 2-10, the mapping processor comprising: a first filter configured to filter the electrical signal across a first time scale to generate a first filtered signal, wherein the first filter comprises a first frequency response; a second filter configured to filter the electrical signal across a second time scale to generate a second filtered signal, wherein the second filter comprises a second frequency response, wherein at least a portion of the frequency response of the second filter is lower than a corresponding portion of the frequency response of the first filter; and a feature detector configured to determine a feature corresponding to sharpness by analyzing the first and second filtered signals, wherein the display device is configured to depict a change in the determined feature over time.


In Example 12, the system of Example 11, wherein at least one of the first and second filters is configured to determine at least one of a time difference of the electrical signal, an approximate derivative of the electrical signal, a slope estimate across a time window, and a wavelet decomposition of the electrical signal.


In Example 13, the system of any of Examples 11 and 12, wherein at least one of the first and second filters is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.


In Example 14, the system of any of Examples 1-13, wherein the mapping processor is further configured to determine an overall morphology change of the electrogram based on a pre-ablation deflection template.


In Example 15, the system of Example 14, wherein the change in morphology is determined using at least one of a matched filter, a correlation, and a convolution with the pre-ablation deflection template or a signal derived therefrom.


In Example 16, the system of any of Examples 2-15, wherein the display device is configured to display a waveform.


In Example 17, the system of Example 16, the waveform representing at least one of the filtered signal, an envelope of the filtered signal, an amplitude of the filtered signal, and a power of the filtered signal.


In Example 18, the system of any of Examples 16 and 17, wherein the output component is configured to determine a combined signal comprising a combination of the filtered signal with an additional filtered signal, the waveform representing at least one of the combined signal, an envelope of the combined signal, an amplitude of the combined signal, and a power of the combined signal.


In Example 19, a method for evaluating a condition of myocardial tissue, the method comprising: positioning a catheter adjacent to myocardial tissue within a patient's body, the catheter comprising: a flexible catheter body having a distal portion; and at least one electrode disposed on the distal portion, the at least one electrode configured to measure an electrical signal based on a cardiac activation signal; receiving the electrical signal; providing an electrogram based on the electrical signal; determining at least one of a sharpness of the electrogram and a characteristic of a morphology of the electrogram, the characteristic of the morphology of the electrogram relating to the sharpness; and displaying at least one of an indication of the sharpness and an indication of the characteristic of the morphology, wherein the indication comprises at least one of a map, a light indicator, and a waveform.


In Example 20, the method of Example 19, wherein the catheter comprises an ablation catheter including a tissue ablation electrode configured to apply ablation energy to tissue, the method further comprising performing an ablation of a portion of the tissue.


In Example 21, method of Example 20, further comprising determining the characteristic of the morphology of the electrogram before an ablation, during an ablation, and/or after an ablation.


In Example 22, the method of any of Examples 19-21, further comprising filtering, using a filter, the electrical signal to generate a filtered signal.


In Example 23, the method of Example 22, wherein the electrical signal is unipolar, and wherein filtering the electrical signal comprises applying a nonlinear processing technique to the electrogram to retain only negative deflections.


In Example 24, the method of any of Examples 22 and 23, wherein filtering the electrical signal comprises approximating a derivative of the electrical signal, the method further comprising determining a relative change in an amplitude of the filtered signal during a period of time, wherein the indication of the characteristic of the morphology indicates the relative change in the amplitude of the filtered signal during the period of time.


In Example 25, the method of Example 24, wherein the amplitude comprises at least one of an absolute amplitude, a root-mean-squared (RMS) measurement, a peak-to-peak measurement, a maximum of a peak-to-peak measurement over a window, a percentile range measurement, a beat-gated measurement, and a free-running measurement.


In Example 26, the method of any of Examples 22-25, wherein the filter is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.


In Example 27, the method of any of Examples 22-26, wherein the filter includes a nonlinear processing element configured to attenuate one or more components of the electrical signal based on a polarity of a deflection of the electrical signal.


In Example 28, the method of any of Examples 22-27, wherein the filter comprises a half-wave rectifier.


In Example 29, the method of any of Examples 19-28, further comprising: filtering the electrical signal across a first time scale to generate a first filtered signal, wherein the first filter comprises a first frequency response; filtering the electrical signal across a second time scale to generate a second filtered signal, wherein the second filter comprises a second frequency response, wherein at least a portion of the frequency response of the second filter is lower than a corresponding portion of the frequency response of the first filter; determining a feature corresponding to sharpness by analyzing the first and second filtered signals; and providing an output to a display device, wherein the output comprises the determined feature, wherein the display device is configured to depict a change in the determined feature over time.


In Example 30, the method of Example 29, wherein at least one of the first and second filters is configured to determine at least one of a time difference of the electrical signal, a derivative of the electrical signal, a slope estimate across a time window, and a wavelet decomposition of the electrical signal.


In Example 31, the method of any of Examples 29 and 30, wherein at least one of the first and second filters is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.


In Example 32, the method of any of Examples 19-31, further comprising determining an overall morphology change of the electrogram based on a pre-ablation deflection template.


In Example 33, the method of Example 32, wherein the change in morphology is determined using at least one of a matched filter, a correlation, and a convolution with the pre-ablation deflection template or a signal derived therefrom.


In Example 34, the method of any of Examples 19-33, the waveform representing at least one of the filtered signal, an envelope of the filtered signal, an amplitude of the filtered signal, and a power of the filtered signal.


In Example 35, the method of any of Examples 19-34, further comprising determining a combined signal comprising a combination of the filtered signal with an additional filtered signal, the waveform representing at least one of the combined signal, an envelope of the combined signal, an amplitude of the combined signal, and a power of the combined signal.


In Example 36, a system includes a catheter including a flexible catheter body having a distal portion; and at least one electrode disposed on the distal portion, the at least one electrode configured to measure an electrical signal based on a cardiac activation signal. The system also includes a mapping processor configured to acquire the electrical signal from the at least one electrode, provide an electrogram based on the electrical signal, determine at least one of a sharpness associated with the electrogram and a characteristic of a morphology of the electrogram, wherein the characteristic of the morphology of the electrogram is related to the sharpness.


In Example 37, the system of Example 36, wherein the catheter comprises an ablation catheter including a tissue ablation electrode configured to apply ablation energy to tissue, the system further comprising a radiofrequency (RF) generator operatively coupled to the tissue ablation electrode, wherein the RF generator is configured to generate the ablation energy and convey the generated ablation energy to the tissue ablation electrode.


In Example 38, the system of Example 37, wherein the mapping processor is configured to determine the sharpness before an ablation, during an ablation, and/or after an ablation.


In Example 39, the system of Example 36, further comprising a display device, wherein the mapping processor comprises: a filter configured to filter the electrical signal to generate a filtered signal; a feature detector configured to determine an amplitude of the filtered signal; and an output component configured to provide an output to the display device, wherein the output comprises the determined amplitude of the filtered signal.


In Example 40, the system of Example 39, wherein the amplitude comprises at least one of an absolute amplitude, a root-mean-squared (RMS) measurement, a peak-to-peak measurement, a maximum of a peak-to-peak measurement over a window, a percentile range measurement, a beat-gated measurement, and a free-running measurement.


In Example 41, the system of Example 39, wherein the filter is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.


In Example 42, the system of Example 39, wherein the filtered signal comprises an approximate derivative of the electrical signal.


In Example 43, the system of Example 39, wherein the filter includes a nonlinear processing element configured to attenuate one or more components of the electrical signal based on a polarity of a deflection of the electrical signal.


In Example 44, the system of Example 43, wherein the filter comprises a half-wave rectifier.


In Example 45, the system of Example 39, wherein the display device is configured to indicate a relative change in the amplitude of the filtered signal during a period of time.


In Example 46, the system of Example 39, wherein the display device is configured to display a waveform.


In Example 47, the system of Example 46, the waveform representing at least one of the filtered signal, an envelope of the filtered signal, an amplitude of the filtered signal, and a power of the filtered signal.


In Example 48, the system of Example 46, wherein the output component is configured to determine a combined signal comprising a combination of the filtered signal with an additional filtered signal, the waveform representing at least one of the combined signal, an envelope of the combined signal, an amplitude of the combined signal, and a power of the combined signal.


In Example 49, the system of Example 36, further comprising a display device, the mapping processor comprising: a first filter configured to filter the electrical signal across a first time scale to generate a first filtered signal, wherein the first filter comprises a first frequency response; a second filter configured to filter the electrical signal across a second time scale to generate a second filtered signal, wherein the second filter comprises a second frequency response, wherein at least a portion of the frequency response of the second filter is lower than a corresponding portion of the frequency response of the first filter; a feature detector configured to determine a feature corresponding to sharpness by analyzing the first and second filtered signals; and an output component configured to provide an output to the display device, wherein the output comprises the determined feature, wherein the display device is configured to depict a change in the determined feature over time.


In Example 50, the system of Example 49, wherein at least one of the first and second filters is configured to determine at least one of a time difference of the electrical signal, an approximate derivative of the electrical signal, a slope estimate across a time window, and a wavelet decomposition of the electrical signal.


In Example 51, the system of Example 49, wherein at least one of the first and second filters is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.


In Example 52, the system of Example 49, wherein the feature detector is configured to assess the sharpness of the electrical signal by comparing one or more levels of the first filtered signal with one or more levels of the second filtered signal to determine an amplitude-invariant measure of sharpness.


In Example 53, the system of Example 36, wherein the mapping processor is further configured to determine an overall morphology change of the electrogram based on a pre-ablation deflection template.


In Example 54, the system of Example 53, wherein the change in morphology is determined using at least one of a matched filter, a correlation, and a convolution with the pre-ablation deflection template or a signal derived therefrom.


In Example 55, a method for evaluating a condition of myocardial tissue includes positioning a catheter adjacent to myocardial tissue within a patient's body, the catheter including a flexible catheter body having a distal portion, at least one electrode disposed on the distal portion, wherein the at least one electrode is configured to measure an electrical signal based on a cardiac activation signal; receiving the electrical signal; providing an electrogram based on the electrical signal; determining at least one of a sharpness of the electrogram and a characteristic of a morphology of the electrogram, the characteristic of the morphology of the electrogram relating to the sharpness of the electrogram; and displaying an indication of at least one of the sharpness and the characteristic of the morphology, wherein the indication comprises at least one of a map, a light indicator, and a waveform.


In Example 56, the method of Example 55, wherein the catheter comprises an ablation catheter including a tissue ablation electrode configured to apply ablation energy to tissue, the method further comprising performing an ablation of a portion of the tissue.


In Example 57, the method of Example 56, further comprising determining the characteristic of the morphology of the electrogram before an ablation, during an ablation, and/or after an ablation.


In Example 58, the method of Example 55, further comprising filtering, using a filter, the electrical signal to generate a filtered signal.


In Example 59, the method of Example 58, wherein the electrical signal is unipolar, and wherein filtering the electrical signal comprises applying a nonlinear processing technique to the electrogram to retain only negative deflections.


In Example 60, the method of Example 59, wherein applying the nonlinear processing technique comprises applying a half-wave rectifier to the electrogram.


In Example 61, the method of Example 58, wherein filtering the electrical signal comprises approximating a derivative of the electrical signal, the method further comprising determining a relative change in an amplitude of the filtered signal during a period of time, wherein the indication of the characteristic of the morphology indicates the relative change in the amplitude of the filtered signal during the period of time.


In Example 62, the method of Example 61, wherein the amplitude comprises at least one of an absolute amplitude, a root-mean-squared (RMS) measurement, a peak-to-peak measurement, a maximum of a peak-to-peak measurement over a window, a percentile range measurement, a beat-gated measurement, and a free-running measurement.


In Example 63, the method of Example 58, wherein the filter is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.


In Example 64, the method of Example 55, further comprising: filtering the electrical signal across a first time scale, using a first filter, to generate a first filtered signal, wherein the first filter comprises a first frequency response; filtering the electrical signal across a second time scale, using a second filter, to generate a second filtered signal, wherein the second filter comprises a second frequency response, wherein at least a portion of the frequency response of the second filter is lower than a corresponding portion of the frequency response of the first filter; determining a feature corresponding to sharpness by analyzing the first and second filtered signals; and providing an output to a display device, wherein the output comprises the determined feature, wherein the display device is configured to depict a change in the determined feature over time.


In Example 65, the method of Example 64, wherein at least one of the first and second filters is configured to determine at least one of a time difference of the electrical signal, a derivative of the electrical signal, a slope estimate across a time window, and a wavelet decomposition of the electrical signal.


In Example 66, the method of Example 64, wherein at least one of the first and second filters is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.


In Example 67, the method of Example 64, further comprising determining an overall morphology change of the electrogram based on a pre-ablation deflection template.


In Example 68, the method of Example 67, wherein the change in morphology is determined using at least one of a matched filter, a correlation, and a convolution with the pre-ablation deflection template or a signal derived therefrom.


In Example 69, the method of Example 64, the waveform representing at least one of the filtered signal, an envelope of the filtered signal, an amplitude of the filtered signal, and a power of the filtered signal.


In Example 70, the method of Example 65, further comprising determining a combined signal comprising a combination of the filtered signal with an additional filtered signal, the waveform representing at least one of the combined signal, an envelope of the combined signal, an amplitude of the combined signal, and a power of the combined signal.


In Example 71, a system includes an ablation catheter including a flexible catheter body having a distal portion, a tissue ablation electrode disposed on the distal portion of the flexible catheter body, wherein the tissue ablation electrode is configured to apply ablation energy to tissue. The system also includes at least one electrode disposed on the distal portion, the at least one electrode configured to measure an electrical signal based on a cardiac activation signal; and a radiofrequency (RF) generator operatively coupled to the tissue ablation electrode and configured to generate the ablation energy to be conveyed to the tissue ablation electrode. The system further includes a mapping processor configured to: acquire the electrical signal from the at least one electrode; provide an electrogram based on the electrical signal; determine at least one of a sharpness associated with the electrogram and a characteristic of a morphology of the electrogram, the characteristic relating to the sharpness.


While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic illustration of a radio frequency (RF) ablation system in accordance with embodiments of the present invention.



FIG. 2 is a block diagram depicting an illustrative mapping operating environment in accordance with embodiments of the present invention.



FIG. 3 is a flow diagram depicting an illustrative method of analyzing morphology of an electrogram in accordance with embodiments of the present invention.



FIG. 4 is a schematic block diagram depicting an illustrative process flow for analyzing morphology of an electrogram in accordance with embodiments of the present invention.



FIG. 5 depicts an illustrative electrogram and filtered electrogram in accordance with embodiments of the present invention.



FIG. 6 is a schematic block diagram depicting another illustrative process flow for analyzing morphology of an electrogram in accordance with embodiments of the present invention.





While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.


DETAILED DESCRIPTION

Electrophysiologists may utilize any number of metrics to assess the formation and transmurality of lesions. These include, for example, bipolar electrogram amplitude drop, ablation impedance drop, and pacing capture threshold. Electrogram amplitude, measured from peak to peak of a given bipolar electrogram deflection, provides a measure of myocardium viability. However, it does not quantify the morphology of the electrogram, which may contain additional information about lesion formation, especially in unhealthy tissue. In unhealthy tissue (e.g., tissue afflicted by edema, scar tissue, etc.), amplitude reduction due to damage to the local surviving tissue may be obscured by the much stronger far-field signal. However, damage to the local tissue may make some components of the electrogram change less rapidly as compared to when the local tissue was healthy. Quantifying electrogram morphology before, during, and after an ablation, by analyzing sharpness of the electrogram, may facilitate aiding electrophysiologists in evaluating the formation of lesions. Real-time morphology analysis may facilitate enabling electrophysiologists to determine a minimum amount of time required for each ablation, reducing the amount of radiofrequency (RF) energy delivered during procedures.


According to various embodiments, measuring sharpness may include assigning a time-varying value to an electrogram. For example, sharpness may be quantified using an approximate derivative calculated at various temporal scales. The values may be used, in a relative manner, throughout an ablation in order to gauge the progressive change of morphology. Embodiments of the invention may be implemented using specialty catheters or catheters already commercially available. Embodiments include a hardware/software graphical user interface (GUI) used for acquiring electrical signals, performing sharpness analyses, and displaying the results during an ablation procedure. This may be accomplished, for example, with a stand-alone system or may be incorporated into existing systems such as the Bard LabSystem Pro or the Rhythmia Mapping System, both available from Boston Scientific Corporation of Marlborough, Mass.



FIG. 1 is a schematic illustration of a radio frequency (RF) ablation system 100 in accordance with embodiments of the present invention. As shown in FIG. 1, the system 100 includes an ablation catheter 102, an RF generator 104, and a mapping processor 106. The ablation catheter 102 is operatively coupled to both the RF generator 104 and the mapping processor 106, as will be described in greater detail herein. As is further shown, the ablation catheter 102 includes a proximal handle 108 having an actuator 110 (e.g., a control knob, lever, or other actuator), a flexible body 112 having a distal portion 114 including a plurality of ring electrodes 116, a tissue ablation electrode 118, and a plurality of mapping electrodes 120 (also referred to herein as “pin” electrodes) disposed or otherwise positioned within and/or electrically isolated from the tissue ablation electrode 118. In various embodiments, the catheter system 100 may also include noise artifact isolators (not shown), wherein the electrodes 120 are electrically insulated from the exterior wall by the noise artifact isolators.


In some instances, the ablation system 100 may be utilized in ablation procedures on a patient and/or in ablation procedures on other objects. In various embodiments, the ablation catheter 102 may be configured to be introduced into or through the vasculature of a patient and/or into or through any other lumen or cavity. In an example, the ablation catheter 102 may be inserted through the vasculature of the patient and into one or more chambers of the patient's heart (e.g., a target area). When in the patient's vasculature or heart, the ablation catheter 102 may be used to map and/or ablate myocardial tissue using the ring electrodes 116, the electrodes 120 and/or the tissue ablation electrode 118. In embodiments, the tissue ablation electrode 118 may be configured to apply ablation energy to myocardial tissue of the heart of a patient.


The catheter 102 may be steerable to facilitate navigating the vasculature of a patient or navigating other lumens. For example, the distal portion 114 of the catheter 102 may be configured to be deflected (as indicated by the dashed outlines in FIG. 1) by manipulation of the actuator 110 to effect steering the catheter 102. In some instances, the distal portion 114 of the catheter 102 may be deflected to position the tissue ablation electrode 118 and/or the electrodes 120 adjacent target tissue or to position the distal portion 114 of the catheter 102 for any other purpose. Additionally, or alternatively, the distal portion 114 of the catheter 102 may have a pre-formed shape adapted to facilitate positioning the tissue ablation electrode 118 and/or the electrodes 120 adjacent a target tissue. For example, the preformed shape of the distal portion 114 of the catheter 102 may include a radial shape (e.g., a generally circular shape or a generally semi-circular shape) and/or may be oriented in a plane transverse to a general longitudinal direction of the catheter 102.


In various embodiments, the electrodes 120 are circumferentially distributed about the tissue ablation electrode 118 and electrically isolated therefrom. The electrodes 120 can be configured to operate in unipolar or bipolar sensing modes. In some embodiments, the plurality of electrodes 120 may define and/or at least partially form one or more bipolar electrode pairs, each bipolar electrode pair being configured to measure an electrical signal corresponding to a sensed electrical activity (e.g., an electrogram (EGM) reading) of the myocardial tissue proximate thereto. The measured signals from the electrodes 120 can be provided to the mapping processor 106 for processing as described herein. In embodiments, an EGM reading or signal from a bipolar electrode pair may at least partially form the basis of a contact assessment, ablation area assessment (e.g., tissue viability assessment), and/or an ablation progress assessment (e.g., a lesion formation/maturation analysis), as discussed below.


Various embodiments may include, instead of, or in addition to, an ablation catheter 102, a mapping catheter (not shown) that includes mapping electrodes such as, for example, the electrodes 120, but does not necessarily include a tissue ablation electrode 118. In embodiments, for example, a mapping catheter may be utilized for mapping while performing an ablation with a separate ablation catheter (e.g., the ablation catheter 102), or independently of performing tissue ablation. In other embodiments, more than one mapping catheter may be used to enhance the mapping data. Additionally or alternatively to the circumferentially spaced electrodes 120, the catheter 102 may include one or more forward facing electrodes (not shown). The forward facing electrodes may be generally centrally located within the tissue ablation electrode 118 and/or at an end of a tip of the catheter 102.


The tissue ablation electrode 118 may be any length and may have any number of the electrodes 120 positioned therein and spaced circumferentially and/or longitudinally about the tissue ablation electrode 118. In some instances, the tissue ablation electrode 118 may have a length of between one (1) mm and twenty (20) mm, three (3) mm and seventeen (17) mm, or six (6) mm and fourteen (14) mm. In one illustrative example, the tissue ablation electrode 118 may have an axial length of about eight (8) mm.


In some cases, the plurality of electrodes 120 may be spaced at any interval about the circumference of the tissue ablation electrode 118. In one example, the tissue ablation electrode 118 may include at least three electrodes 120 equally or otherwise spaced about the circumference of the tissue ablation electrode 118 and at the same or different longitudinal positions along the longitudinal axis of the tissue ablation electrode 118. In some illustrative instances, the tissue ablation electrode 118 may have an exterior wall that at least partially defines an open interior region (not shown). The exterior wall may include one or more openings for accommodating one or more electrodes 120. Additionally, or alternatively, the tissue ablation electrode 118 may include one or more irrigation ports (not shown). Illustratively, the irrigation ports, when present, may be in fluid communication with an external irrigation fluid reservoir and pump (not shown) which may be used to supply fluid (e.g., irrigation fluid) to myocardial tissue to be or being mapped and/or ablated.


The RF generator 104 may be configured to deliver ablation energy to the ablation catheter 102 in a controlled manner in order to ablate the target tissue sites identified by the mapping processor 106. Ablation of tissue within the heart is well known in the art, and thus for purposes of brevity, the RF generator 104 will not be described in further detail. Further details regarding RF generators are provided in U.S. Pat. No. 5,383,874, which is expressly incorporated herein by reference in its entirety for all purposes. Although the mapping processor 106 and RF generator 104 are shown as discrete components, they can alternatively be incorporated into a single integrated device.


The RF ablation catheter 102 as described may be used to perform various diagnostic functions to assist the physician in an ablation treatment. For example, in some embodiments, the catheter 102 may be used to ablate cardiac arrhythmias, and at the same time provide real-time assessment of a lesion formed during RF ablation. Real-time assessment of the lesion may involve any of monitoring surface and/or tissue temperature at or around the lesion, reduction in the electrocardiogram signal, a drop in impedance, direct and/or surface visualization of the lesion site, and imaging of the tissue site (e.g., using computed tomography, magnetic resonance imaging, ultrasound, etc.). In addition, the presence of the electrodes within the RF tip electrode can operate to assist the physician in locating and positioning the tip electrode at the desired treatment site, and to determine the position and orientation of the tip electrode relative to the tissue to be ablated.


Illustrative catheters that may be used as the catheter 102 may include, among other ablation and/or mapping catheters, those described in U.S. patent application Ser. No. 12/056,210 filed on Mar. 26, 2008, and entitled HIGH RESOLUTION ELECTROPHYSIOLOGY CATHETER, and U.S. Pat. No. 8,414,579 filed on Jun. 23, 2010, entitled MAP AND ABLATE OPEN IRRIGATED HYBRID CATHETER, which are both hereby incorporated herein by reference in their entireties for all purposes. Alternatively, or in addition, catheters that may be used as the catheter 102 may include, among other ablation and/or mapping catheters, those described in U.S. Pat. No. 5,647,870 filed on Jan. 16, 1996, as a continuation of U.S. Ser. No. 206,414, filed Mar. 4, 1994 as a continuation-in-part of U.S. Ser. No. 33,640, filed Mar. 16, 1993, entitled MULTIPLE ELECTRODE SUPPORT STRUCTURES, U.S. Pat. No. 6,647,281 filed on Apr. 6, 2001, entitled EXPANDABLE DIAGNOSTIC OR THERAPEUTIC APPARATUS AND SYSTEM FOR INTRODUCING THE SAME INTO THE BODY, and U.S. Pat. No. 8,128,617 filed on May 27, 2008, entitled ELECTRICAL MAPPING AND CRYO ABLATING WITH A BALLOON CATHETER, which are all hereby incorporated herein by reference in their entireties for all purposes.


In operation and when the catheter 102 is within a patient and/or adjacent a target area, the catheter 102 may sense electrical signals (e.g., EGM signals) from the patient or target area and relay those electrical signals to a physician (e.g., through the display of the RF ablation system 100). Electrophysiologists and/or others may utilize an EGM amplitude and/or EGM morphology to verify a location of the ablation catheter in a patient's anatomy, to verify viability of tissue adjacent the ablation catheter, to verify lesion formation in tissue adjacent the ablation catheter, and/or to verify or identify other characteristics related to the catheter 102 and/or adjacent target tissue or areas.


Based, at least in part, on its sensing capabilities, the catheter 102 may be utilized to perform various diagnostic functions to assist the physician in ablation and/or mapping procedures, as referred to above and discussed further below. In one example, the catheter 102 may be used to ablate cardiac arrhythmias, and at the same time provide real-time positioning information, real-time tissue viability information, and real-time assessment of a lesion formed during ablation (e.g., during RF ablation). Real-time assessment of the lesion may involve monitoring surfaces and/or tissue temperature at or around the lesion, reduction in the electrogram signal amplitude and/or spectrum, a change in impedance (e.g., an increase or decrease), direct and/or surface visualization of the lesion site, and/or imaging of a tissue site (e.g., using computed tomography, magnetic resonance imaging, ultrasound, etc.). “Real-time”, as used herein and understood in the art, means during an action or process. For example, where one is monitoring frequency spectra in real time during an ablation at a target area, the frequency spectra are being monitored during the process of ablating at a target area (e.g., between applications of ablation energy). Additionally, or alternatively, the presence of electrodes 120 at or about the tissue ablation electrode 118 and/or within the tip (e.g., at the distal tip) of the catheter 102 may facilitate allowing a physician to locate and/or position the tissue ablation electrode 118 at a desired treatment site, to determine the position and/or orientation of the tissue ablation electrode relative to the tissue that is to be ablated or relative to any other feature.



FIG. 2 depicts an illustrative mapping operating environment 200 in accordance with embodiments of the present invention. In various embodiments, a mapping processor 202 (which may be, or be similar to, mapping processor 106 depicted in FIG. 1) may be configured to detect, process, and record electrical signals associated with myocardial tissue via a catheter such as the ablation catheter 102 depicted in FIG. 1, a mapping catheter, and/or the like. In embodiments, based on these electrical signals, a physician can identify the specific target tissue sites within the heart, and ensure that the arrhythmia causing substrates have been electrically isolated by the ablative treatment. The mapping processor 202 is configured to process signals from electrodes 204 (which may include, e.g., electrodes 120 and/or ring electrodes 116 depicted in FIG. 1), and to generate an output to a display device 206. The display device 206 may be configured to present an indication of a tissue condition, effectiveness of an ablation procedure, and/or the like (e.g., for use by a physician). In some embodiments, the display device 206 may include electrocardiogram (ECG) information, which may be analyzed by a user to determine the existence and/or location of arrhythmia substrates within the heart and/or determine the location of an ablation catheter within the heart. In various embodiments, the output from the mapping processor 202 can be used to provide, via the display device 206, an indication to the clinician about a characteristic of the ablation catheter and/or the myocardial tissue being mapped.


In instances where an output is generated to a display device 206 and/or other instances, the mapping processor 202 may be operatively coupled to or otherwise in communication with the display device 206. In embodiments, the display device 206 may include various static and/or dynamic information related to the use of an RF ablation system (e.g., the RF ablation system 100 depicted in FIG. 1). For example, the display device 206 may present an image of the target area, an image of the catheter, and/or information related to EGMs, which may be analyzed by the user and/or by a processor of the RF ablation system to determine the existence and/or location of arrhythmia substrates within the heart, to determine the location of the catheter within the heart, and/or to make other determinations relating to use of the catheter and/or other catheters.


In embodiments, the display device 206 may be an indicator. The indicator may be capable of providing an indication related to a feature of the output signals received from one or more of the electrodes 204. For example, an indication to the clinician about a characteristic of the catheter and/or the myocardial tissue interacted with and/or being mapped may be provided on the display device 206. In some cases, the indicator may provide a visual and/or audible indication to provide information concerning the characteristic of the catheter and/or the myocardial tissue interacted with and/or being mapped. In embodiments, the visual indication may take one or more forms. In some instances, a visual color or light indication on a display 206 may be separate from or included on an imaged catheter on the display 206 if there is an imaged catheter. Such a color or light indicator may include a progression of lights or colors that may be associated with various levels of a characteristic proportional to the amplitude and/or spectrum of an EGM. Alternatively, or in addition, an indicator indicating a level of a characteristic proportional to an amplitude and/or spectrum of an EGM may be provided in any other manner on a display and/or with any audible or other sensory indication, as desired.


In some cases, a visual indication may be an indication on a display device 206 (e.g., a computer monitor, touchscreen device, and/or the like) with one or more lights or other visual indicators. In one example of an indicator, a color of at least a portion of an electrode of a catheter imaged on a screen of the display 206 may change from a first color (e.g., red or any other color) when there is poor contact between the catheter and tissue to a second color (e.g., green or any other color different than the first color) when there is good contact between the catheter and the tissue and/or when ablation may be initiated after establishing good contact. Additionally or alternatively in another example of an indicator, when the amplitude and/or frequency spectrum of the EGM stops changing and/or reaches a lesion maturation amplitude or frequency spectrum threshold, a depicted color of an electrode on the imaged catheter may change colors to indicate a level of lesion maturation. In a similar manner, an indicator may be utilized to indicate a viability of tissue to be ablated. In the examples above, the changing color/light or changing other indicator (e.g., a number, an image, a design, etc.) may be located at a position on the display other than on the imaged catheter, as desired. According to embodiments, indicators may provide any type of information to a user. For example, the indicators discussed herein may be pass or fail type indicators showing when a condition is present or is not present and/or may be progressive indicators showing the progression from a first level to a next level of a characteristic.


According to embodiments, various components (e.g., the mapping processor 202) of the operating environment 200, illustrated in FIG. 2, may be implemented on one or more computing devices. A computing device may include any type of computing device suitable for implementing embodiments of the disclosure. Examples of computing devices include specialized computing devices or general-purpose computing devices such “workstations,” “servers,” “laptops,” “desktops,” “tablet computers,” “hand-held devices,” and the like, all of which are contemplated within the scope of FIG. 2 with reference to various components of the operating environment 200.


In embodiments, a computing device includes a bus that, directly and/or indirectly, couples the following devices: a processing unit (e.g., the processing unit 208 depicted in FIG. 2), a memory (e.g., the memory 210 depicted in FIG. 2), an input/output (I/O) port, an I/O component (e.g., the output component 212 depicted in FIG. 2), and a power supply. Any number of additional components, different components, and/or combinations of components may also be included in the computing device. The bus represents what may be one or more busses (such as, for example, an address bus, data bus, or combination thereof). Similarly, in embodiments, the computing device may include a number of processing units (which may include, for example, hardware, firmware, and/or software computer processors), a number of memory components, a number of I/O ports, a number of I/O components, and/or a number of power supplies. Additionally any number of these components, or combinations thereof, may be distributed and/or duplicated across a number of computing devices.


In embodiments, the memory 210 includes computer-readable media in the form of volatile and/or nonvolatile memory and may be removable, nonremovable, or a combination thereof. Media examples include Random Access Memory (RAM); Read Only Memory (ROM); Electronically Erasable Programmable Read Only Memory (EEPROM); flash memory; optical or holographic media; magnetic cassettes, magnetic tape, magnetic disk storage or other magnetic storage devices; data transmissions; or any other medium that can be used to store information and can be accessed by a computing device such as, for example, quantum state memory, and the like.


In embodiments, the memory 210 stores computer-executable instructions for causing the processing unit 208 to implement aspects of embodiments of system components and/or to perform aspects of embodiments of methods and procedures discussed herein. Computer-executable instructions may include, for example, computer code, machine-useable instructions, and the like such as, for example, program components capable of being executed by one or more processors associated with a computing device. Examples of such program components include a filter component 214 and a feature detector 216. Program components may be programmed using any number of different programming environments, including various languages, development kits, frameworks, and/or the like. Some or all of the functionality contemplated herein may also be implemented in hardware and/or firmware.


The illustrative operating environment 200 shown in FIG. 2 is not intended to suggest any limitation as to the scope of use or functionality of embodiments of the present disclosure. Neither should it be interpreted as having any dependency or requirement related to any single component or combination of components illustrated therein. Additionally, any one or more of the components depicted in FIG. 2 may be, in embodiments, integrated with various ones of the other components depicted therein (and/or components not illustrated), all of which are considered to be within the ambit of the present disclosure. For example, the filter component 214 may be integrated with the feature detector 216. In embodiments, any number of components such as those depicted in FIG. 2 may be utilized to analyze EGM data, as described herein.


For example, in embodiments, EGM amplitude may be determined and/or measured in real-time by the mapping processor 202, e.g., from peak to peak of an EGM deflection or from the ST segment of the P-QRS-T curve of an EGM reading or signal in a time domain, and may quantify an intensity of an EGM signal and provide information relating to one or more target area characteristics. In embodiments, some target area characteristics include, but are not limited to, contact force between the catheter 102 and tissue, viability of tissue, and lesion maturation.


In some instances, EGM data may be further analyzed in a meaningful manner in real-time (e.g., during a typical electrophysiology procedure) by determining a sharpness feature associated with the EGM and determining, based on the sharpness feature, a characteristic of morphology of the EGM. In embodiments, determining the sharpness feature may include filtering an EGM signal with the mapping processor 202 and/or other processor and analyzing the resulting filtered signal or signals. Such an analysis of filtered signals derived from an EGM signal may enhance EGM data interpretation and may allow for real-time insights related to contact assessments, viable versus non-viable tissue, and/or lesion maturation during an ablation procedure, among other real-time insights.


Illustratively, any technique, as desired, may be utilized (e.g., by the filter component 214) to filter an EGM signal. For example, the filter component 214 may be configured to determine an approximate derivative of the EGM signal, apply frequency filters to the EGM signal across various time scales, apply a half-wave rectifier or other nonlinear processing to unipolar EGM signals, apply matched filters to the EGM signal, and/or the like. In embodiments, for example, the filter component 214 may be configured to filter the EGM to generate a filtered signal, and the feature detector 216 may be configured to determine a feature (e.g., an amplitude, an envelope, a power, etc.) of the filtered signal. The filter component 214 may, in embodiments, include any number of nonlinear processing elements configured to attenuate one or more components of a signal, e.g., based on the polarity of the deflection of the signal. For example, a matched filter may be used to quantify overall morphology of the EGM. For example, the filter component 214 may select a pre-ablation deflection template (or signal derived therefrom) and correlate it, and/or convolute it, with one or more deflections received during and/or after ablation. In this manner, for example, the feature detector 216 may be used to determine a maximum normalized correlation of the template with each subsequent deflection, which may represent, for example, an amplitude-independent change in morphology of the EGM over time.


The output component 212 may be configured to provide an output to the display device 206, where the output includes the determined feature (e.g., an amplitude computed over a window such as a window that is related to one or more beat events) of the filtered signal. For example, the display device 206 may be configured to indicate a relative change in the amplitude of the filtered signal during a period of time. According to embodiments, the amplitude may include a root-mean-squared (RMS) amplitude calculation, a power calculation, a peak-to-peak calculation, a percentile range calculation, a beat-gated amplitude, a free-running amplitude, and/or the like. In embodiments, the display device 206 may be configured to display a waveform. The waveform may, for example, represent the filtered signal, an envelope of the filtered signal, an amplitude of the filtered signal, a power of the filtered signal, a combined signal (e.g., a combination of the filtered signal with an additional filtered signal), an envelope of a combined signal, an amplitude of a combined signal, a power of a combined signal, and/or the like. A combined signal may, for example, be generated by averaging the filtered signal and an additional filtered signal, computing a root mean square (RMS) of the two signals, and/or the like.


As described above, in embodiments, a mapping processor (e.g., the mapping processor 106 depicted in FIG. 1 and/or the mapping processor 202 depicted in FIG. 2) may utilize sharpness features of an electrogram (EGM) to analyze morphology of the EGM. FIG. 3 depicts an illustrative method 300 of analyzing morphology of an electrogram in accordance with embodiments of the present invention. In the illustrative method 300, a distal portion of a catheter (e.g., the catheter 102 depicted in FIG. 1, a mapping catheter, and/or the like) may be positioned at a location proximate a target area or target tissue (block 302). A mapping processor (e.g., the mapping processor 106 depicted in FIG. 1 and/or the mapping processor 202 depicted in FIG. 2) may receive electrical signal measurements from one or more electrodes (e.g., the ablation electrode 118 depicted in FIG. 1, the electrodes 120 depicted in FIG. 1, the electrodes 204 depicted in FIG. 2, and/or other electrodes) of the catheter (e.g., the catheter 102 depicted in FIG. 1) adjacent a target area or tissue (block 304). Illustratively, the signals measured by the electrodes of the catheter may be used to provide an EGM (block 306). Providing the EGM may include sampling, resampling, quantizing, band-pass filtering, noise removal, and/or other processing steps to prepare the signal for use in the mapping processor. As is further shown in FIG. 3, embodiments of the illustrative method 300 further include determining a characteristic of morphology of the EGM (block 308) and displaying an indication of the characteristic of morphology (block 310).


According to embodiments, the mapping processor determines a characteristic of morphology of the EGM based on a sharpness feature of the EGM. In embodiments, the mapping processor may filter the EGM (e.g., the electrical signal) to generate a filtered signal and determine a relative change in an amplitude of the filtered signal during a period of time. For example, the mapping processor may filter the EGM by determining an approximate derivative of the measured electrical signal, in which case the indication of the characteristic of the morphology may indicate the relative change in the amplitude of the filtered signal during the period of time, a representation of an envelope of the filtered signal, and/or the like. In embodiments, the mapping processor may determine an approximate first derivative of the EGM, an approximate second derivative of the EGM, and/or approximate derivatives of higher order. In embodiments, by discretely differentiating an EGM over a sliding time window, the mapping processor may emphasize high frequencies and evaluate the relative change in the amplitude of that differentiated EGM at activation times. Approximating a derivative may include applying a filter with a frequency response that increases roughly in proportion to frequency over some frequency range, e.g. a first difference or a first-order high-pass filter. Approximating a derivative may also include estimating the slope of a signal over some time scale, e.g. using a filter that outputs the slope of a linear regression over a sliding time window.


In some instances, an amplitude, relative amplitude, change in amplitude, and/or rate of change in amplitude of the measured electrical signal (e.g., the EGM), filtered signal, and/or the like, may also be identified and/or represented in an indication via a display device (e.g., the display device 206 depicted in FIG. 2). In an illustrative example, the amplitude of a measured electrical signal may be the amplitude of the ST-segment of a P-QRS-T wave of an EGM. Additionally or alternatively, other amplitudes of an electrical signal may be identified. According to embodiments, amplitudes, relative amplitudes, envelopes, and/or the like of an electrical signal (or a filtered signal) may be compared to, combined with, or otherwise analyzed in conjunction with similar measures associated with one or more filtered signals. For instance, providing an indication of the characteristic of morphology may include displaying a waveform that is generated by combining (e.g., via an averaging technique, determining a root mean square (RMS), etc.) one or more filtered signals and/or an electrical signal (e.g., the EGM).


According to embodiments, a level of one or more characteristics may be represented and/or monitored via the determined characteristics of morphology of the EGM. The one or more characteristics may include, for example, contact force between the catheter and a target area (e.g., a target tissue or other target area), viability of a target area, ablation progress (e.g., lesion maturation or other metric of ablation progress), and conduction characteristics of a target area. In embodiments, one or more of these or other characteristics can be represented and/or monitored, as described herein, in real time, for example, while positioning the distal portion of the catheter proximate the target area, while mapping a target area or other object, while applying ablation energy to a target area, and/or while performing any other action with the catheter. The level of the one or more of the characteristics may be displayed visually on a display, may be indicated by an audible indicator, or may be indicated in any other manner. In embodiments, the indication may include a map (e.g., a voltage map, a frequency spectral map, etc.), a light indicator, a waveform, and/or the like.


For example, the EGM signals and/or filtered signals may be displayed on a display or screen for viewing and/or analysis by a user (e.g., a physician, technician, or other user) of the ablation system and/or mapping catheter. As an alternative, or in addition, to displaying the EGM signals and/or filtered signals, an indication of the orientation of the ablation catheter with respect to a target cardiac tissue may be displayed on a display with indicators thereon or thereabout indicating characteristics proportional to the EGM signals and/or filtered signals. Such an indication of the orientation of the catheter may facilitate the user of the ablation system in determining the orientation of the catheter with respect to the target cardiac tissue. A user of the ablation system may manipulate the catheter to modify a position of the catheter with respect to a target cardiac tissue or to change a force applied to the target cardiac tissue in order to obtain various EGM signal readings. Such manipulation of the catheter may facilitate determining the viability of the target/sensed cardiac tissue, as explained, for example, in U.S. Provisional Application No. 61/955,087, “ELECTROPHYSIOLOGY SYSTEM,” filed Mar. 18, 2014; and U.S. application Ser. No. 13/738,562, “ELECTROPHYSIOLOGY SYSTEM AND METHODS,” filed Jan. 10, 2013, each of which is hereby incorporated herein by reference in its entirety for all purposes.



FIG. 4 depicts an illustrative process flow 400 for analyzing morphology of an electrogram in accordance with embodiments of the present invention. As shown in FIG. 4, a pair of electrodes 402, 404 provide a measured electrical signal 406 (e.g., an electrogram) to a filter 408. As discussed above, the electrodes 402, 404 may be, for example, the electrodes 120 depicted in FIG. 1, and may be configured to measure the electrical signal 406 in response to electrical activity detected in myocardial tissue. The filter 408 is configured to filter the measured electrical signal 406 to generate a filtered signal 410. In embodiments, for example, the filter 408 may be, include, or be included within the filter component 214 depicted in FIG. 2. In embodiments, the filtered signal 408 may include one or more derivatives of the electrical signal 406. FIG. 5 depicts an example of an electrical signal 502 measured by electrodes, in this case, a bipolar electrogram. In embodiments, the filter 408 may be configured to determine a first derivative 504 of the electrical signal 502. Although the first derivative 504 is depicted in FIG. 5, in implementations of embodiments of the present invention, the filtered signal 504 need not necessarily be displayed, but may be maintained in a memory as a set of data.


Returning to FIG. 4, the filtered signal 410 is provided to a feature detector 412, which determines a feature 416 of the filtered signal 410. In embodiments, for example, the feature 416 of the filtered signal 410 may include one or more amplitudes (e.g., peak amplitudes 506 depicted in FIG. 5) of the filtered signal 410, an envelope of the filtered signal 410, a frequency or aspect of frequency spectrum of the filtered signal 410, and/or the like. The feature 416 of the filtered signal is received by an output component 418 (e.g., the output component 212 depicted in FIG. 2). In embodiments, the output component 418 is configured to provide an output 420 to a display device 422. The output may include, for example, the determined feature 416 of the filtered signal 410 such as, for example, a set of determined amplitudes of a derivative of the measured electrical signal 406, a measure of a relative change in the amplitude of the filtered signal 410 during a period of time, a waveform corresponding to the envelope of the filtered signal 410, a curve fitted to the amplitudes of the peaks of the filtered signal 410, a numerical representation of one or more of the foregoing, an executable instruction, and/or any other signal configured to cause the display device 422 to display an indication of a characteristic of the morphology of the measured electrical signal 406. As discussed above, the indication may include, for example, a map, a light indicator, and/or a waveform.


The illustrative process flow 400 shown in FIG. 4 is not intended to suggest any limitation as to the scope of use or functionality of embodiments of the present invention. Neither should the illustrative process flow 400 be interpreted as having any dependency or requirement related to any single component or combination of components illustrated therein. That is, for example, the process flow 400 may include any number of filters 408. Additionally, any one or more of the components depicted in FIG. 4 may be, in embodiments, integrated with various ones of the other components depicted therein (and/or components not illustrated), all of which are considered to be within the ambit of the present invention.



FIG. 6 depicts another illustrative process 600 for analyzing morphology of an electrogram in accordance with embodiments of the present invention. As shown in FIG. 6, a pair of electrodes 602, 604 provide a measured electrical signal 606 (e.g., an electrogram) to a first filter 608 and a second filter 610. As discussed above, the electrodes 602, 604 may be, for example, the electrodes 120 depicted in FIG. 1, and may be configured to measure the electrical signal 606 in response to electrical activity detected in myocardial tissue. As shown in FIG. 6, the first filter 608 filters the measured electrical signal 606 to generate a first filtered signal 612, and the second filter 610 filters the measured electrical signal 606 to generate a second filtered signal 614. The first and second filtered signals 612 and 614 are provided to a feature detector 616 that is configured to determine a feature corresponding to sharpness of the electrical signal 606 by analyzing the first and second filtered signals 612 and 614. The determined feature 618 is provided to an output component 620 that is configured to provide an output 622 to a display device 624, which may, for example, be configured to depict a change in the determined feature 618 over time.


According to embodiments, the first filter 608 may include a first filter, having a first frequency response, configured to filter the electrical signal 606 across a first time scale to generate the first filtered signal 612. The first filtered signal 612 may, for example, include a first frequency spectrum. Additionally, the second filter 610 may include a second filter, having a second frequency response, configured to filter the electrical signal 606 across a second time scale to generate a second filtered signal 614, and where the second filtered signal 614 includes a second frequency spectrum. In embodiments, at least a portion of the spectrum of the second filtered signal may be lower than a corresponding portion of the frequency spectrum of the first filtered signal. Additionally, in embodiments, the first filter and/or the second filter may be more responsive to high-frequency, and/or quickly-varying components, of the measured electrical signal than to low-frequency, and/or slowly-varying components of the measured electrical signal. High-frequency, low-frequency, quickly-varying, and slowly-varying components of the signal may be determined based on any number of different thresholds or ranges. In embodiments, the filter or filters may be configured to be more responsive to various components such that detection of characteristics of the sharpness of the measured electrical signal, as described herein, is enhanced and/or optimized.


According to various embodiments, at least one of the first and second filters 608 and 610 is configured to determine at least one of a time difference of the measured electrical signal 606, a derivative of the measured electrical signal 606, a slope estimate across a time window, and a wavelet decomposition of the measured electrical signal 606. In embodiments, the feature detector 616 may be configured to combine information corresponding to the first and second filtered signals 612 and 614 across time scales to assess sharpness. For example, the feature detector 616 may be configured to compare filtered signal levels at different scales (e.g., short-term vs. long-term slope) to determine an amplitude-invariant measure of sharpness. In embodiments, the feature detector 616 may be configured to evaluate any number of different characteristics associated with a comparison between the first and second filtered signals such as, for example, frequency or phase shifts, frequency spectrum tilt (e.g., an increase in the amount of high or low frequencies over time as amplitudes decrease), and/or the like.


The illustrative process flow 600 shown in FIG. 6 is not intended to suggest any limitation as to the scope of use or functionality of embodiments of the present invention. Neither should the illustrative process flow 600 be interpreted as having any dependency or requirement related to any single component or combination of components illustrated therein. That is, for example, the process flow 600 may include any number of filters 608, 610. Moreover, the filters 608 and 610 may be configured to operate in series. That is, for example, the second filter 610 may be configured to filter the first filtered signal 612 rather than the electrical signal 606. Additionally, any one or more of the components depicted in FIG. 6 may be, in embodiments, integrated with various ones of the other components depicted therein (and/or components not illustrated), all of which are considered to be within the ambit of the present invention.


Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features, embodiments having additional features, and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.


For example, while bipolar signals have an advantage of reducing far-field signals, one disadvantage is that information in the polarity of deflection may be lost. In a bipolar electrogram, local tissue depolarization may appear as a positive deflection, a negative deflection, or both. In a unipolar electrogram (which can be processed to reduce far-field signals), only negative deflections are indicative of local tissue depolarization. Therefore, embodiments of the present invention, as described herein, may be configured to include a nonlinear processing step to retain only negative deflections, e.g., by a half-wave rectifier after filtering the unipolar EGM, which may result in reduced noise floor and better spatial selectivity.

Claims
  • 1. A system comprising: a catheter including: a flexible catheter body having a distal portion; andat least one electrode disposed on the distal portion, the at least one electrode configured to measure an electrical signal based on a cardiac activation signal; anda mapping processor configured to: acquire the electrical signal from the at least one electrode;provide an electrogram based on the electrical signal;determine a sharpness feature associated with the electrogram and, based on the determined sharpness feature, determine a characteristic of a morphology of the electrogram, wherein the characteristic of the morphology of the electrogram is related to the sharpness.
  • 2. The system of claim 1, wherein the catheter comprises an ablation catheter including a tissue ablation electrode configured to apply ablation energy to tissue, the system further comprising a radiofrequency (RF) generator operatively coupled to the tissue ablation electrode, wherein the RF generator is configured to generate the ablation energy and convey the generated ablation energy to the tissue ablation electrode, and wherein the mapping processor is configured to determine the sharpness before an ablation, during an ablation, and/or after an ablation.
  • 3. The system of claim 1, further comprising a display device, wherein the mapping processor comprises: a filter configured to filter the electrical signal to generate a filtered signal;a feature detector configured to determine an amplitude of the filtered signal; andan output component configured to provide an output to the display device, wherein the output comprises the determined amplitude of the filtered signal.
  • 4. The system of claim 3, wherein the amplitude comprises at least one of an absolute amplitude, a root-mean-squared (RMS) measurement, a peak-to-peak measurement, a maximum of a peak-to-peak measurement over a window, a percentile range measurement, a beat-gated measurement, and a free-running measurement.
  • 5. The system of claim 3, wherein the filter is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.
  • 6. The system of claim 3, wherein the filtered signal comprises an approximate derivative of the electrical signal.
  • 7. The system of claim 3, wherein the filter includes a nonlinear processing element configured to attenuate one or more components of the electrical signal based on a polarity of a deflection of the electrical signal.
  • 8. The system of claim 7, wherein the filter comprises a half-wave rectifier.
  • 9. The system of claim 3, wherein the display device is configured to indicate a relative change in the amplitude of the filtered signal during a period of time.
  • 10. The system of claim 3, wherein the display device is configured to display a waveform representing at least one of the filtered signal, an envelope of the filtered signal, an amplitude of the filtered signal, and a power of the filtered signal.
  • 11. The system of claim 10, wherein the output component is configured to determine a combined signal comprising a combination of the filtered signal with an additional filtered signal, the waveform representing at least one of the combined signal, an envelope of the combined signal, an amplitude of the combined signal, and a power of the combined signal.
  • 12. The system of claim 1, further comprising a display device, the mapping processor comprising: a first filter configured to filter the electrical signal across a first time scale to generate a first filtered signal, wherein the first filter comprises a first frequency response;a second filter configured to filter the electrical signal across a second time scale to generate a second filtered signal, wherein the second filter comprises a second frequency response, wherein at least a portion of the frequency response of the second filter is lower than a corresponding portion of the frequency response of the first filter;a feature detector configured to determine a feature corresponding to sharpness by analyzing the first and second filtered signals; andan output component configured to provide an output to the display device, wherein the output comprises the determined feature, wherein the display device is configured to depict a change in the determined feature over time.
  • 13. The system of claim 12, wherein at least one of the first and second filters is configured to determine at least one of a time difference of the electrical signal, an approximate derivative of the electrical signal, a slope estimate across a time window, and a wavelet decomposition of the electrical signal.
  • 14. The system of claim 12, wherein at least one of the first and second filters is more responsive to high-frequency and/or quickly-varying components of the electrical signal than to low-frequency and/or slowly-varying components of the electrical signal.
  • 15. The system of claim 12, wherein the feature detector is configured to assess the sharpness of the electrical signal by comparing one or more levels of the first filtered signal with one or more levels of the second filtered signal to determine an amplitude-invariant measure of sharpness.
  • 16. The system of claim 1, wherein the mapping processor is further configured to determine an overall morphology change of the electrogram based on a pre-ablation deflection template.
  • 17. The system of claim 16, wherein the change in morphology is determined using at least one of a matched filter, a correlation, and a convolution with the pre-ablation deflection template or a signal derived therefrom.
  • 18. A method for evaluating a condition of myocardial tissue, the method comprising: positioning a catheter adjacent to myocardial tissue within a patient's body, the catheter comprising: a flexible catheter body having a distal portion; andat least one electrode disposed on the distal portion, the at least one electrode configured to measure an electrical signal based on a cardiac activation signal;receiving the electrical signal;providing an electrogram based on the electrical signal;determining a sharpness feature of the electrogram;determining, based on the determined sharpness feature of the electrogram, a characteristic of a morphology of the electrogram, the characteristic of the morphology of the electrogram relating to the sharpness of the electrogram; anddisplaying an indication of at least one of the sharpness and the characteristic of the morphology, wherein the indication comprises at least one of a map, a light indicator, and a waveform.
  • 19. The method of claim 18, further comprising: filtering the electrical signal across a first time scale, using a first filter, to generate a first filtered signal, wherein the first filter comprises a first frequency response;filtering the electrical signal across a second time scale, using a second filter, to generate a second filtered signal, wherein the second filter comprises a second frequency response, wherein at least a portion of the frequency response of the second filter is lower than a corresponding portion of the frequency response of the first filter;determining a feature corresponding to sharpness by analyzing the first and second filtered signals; andproviding an output to a display device, wherein the output comprises the determined feature, wherein the display device is configured to depict a change in the determined feature over time.
  • 20. A system comprising: an ablation catheter including: a flexible catheter body having a distal portion;a tissue ablation electrode disposed on the distal portion of the flexible catheter body, wherein the tissue ablation electrode is configured to apply ablation energy to tissue;at least one electrode disposed on the distal portion, the at least one electrode configured to measure an electrical signal based on a cardiac activation signal; anda radiofrequency (RF) generator operatively coupled to the tissue ablation electrode and configured to generate the ablation energy to be conveyed to the tissue ablation electrode; anda mapping processor configured to: acquire the electrical signal from the at least one electrode;provide an electrogram based on the electrical signal;determine a sharpness feature associated with the electrogram and, based on the determined sharpness feature, determine a characteristic of a morphology of the electrogram, the characteristic relating to the sharpness.
CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority to Provisional Application No. 62/093,771, filed Dec. 18, 2014, which is herein incorporated by reference in its entirety.

US Referenced Citations (474)
Number Name Date Kind
3773401 Douklias et al. Nov 1973 A
4466443 Utsugi Aug 1984 A
4602624 Naples et al. Jul 1986 A
4633882 Matsuo et al. Jan 1987 A
4732149 Sutter Mar 1988 A
4763660 Kroll et al. Aug 1988 A
4966145 Kikumoto et al. Oct 1990 A
5019076 Yamanashi et al. May 1991 A
5029588 Yock et al. Jul 1991 A
5178150 Silverstein et al. Jan 1993 A
5217460 Knoepfler Jun 1993 A
5238004 Sahatjian et al. Aug 1993 A
5240003 Lancee et al. Aug 1993 A
5254088 Lundquist et al. Oct 1993 A
5295482 Clare et al. Mar 1994 A
5318589 Lichtman Jun 1994 A
5324284 Imran Jun 1994 A
5331966 Bennett et al. Jul 1994 A
5334193 Nardella Aug 1994 A
5341807 Nardella Aug 1994 A
5377685 Kazi et al. Jan 1995 A
5383874 Jackson et al. Jan 1995 A
5385146 Goldreyer Jan 1995 A
5385148 Lesh et al. Jan 1995 A
5391199 Ben-Haim Feb 1995 A
5398683 Edwards et al. Mar 1995 A
5423811 Imran et al. Jun 1995 A
5447529 Marchlinski et al. Sep 1995 A
5462521 Brucker et al. Oct 1995 A
5482054 Slater et al. Jan 1996 A
5485849 Panescu et al. Jan 1996 A
5494042 Panescu et al. Feb 1996 A
5500012 Brucker et al. Mar 1996 A
5520683 Subramaniam et al. May 1996 A
5571088 Lennox et al. Nov 1996 A
5573535 Viklund Nov 1996 A
5575772 Lennox Nov 1996 A
5579764 Goldreyer Dec 1996 A
5582609 Swanson et al. Dec 1996 A
5647870 Kordis et al. Jul 1997 A
5718701 Shai et al. Feb 1998 A
5722402 Swanson et al. Mar 1998 A
5762067 Dunham et al. Jun 1998 A
5788636 Curley Aug 1998 A
5792064 Panescu et al. Aug 1998 A
5800482 Pomeranz et al. Sep 1998 A
5820568 Willis Oct 1998 A
5830213 Panescu et al. Nov 1998 A
5833621 Panescu et al. Nov 1998 A
5836990 Li Nov 1998 A
5868735 Lafontaine Feb 1999 A
5871483 Jackson et al. Feb 1999 A
5871526 Gibbs et al. Feb 1999 A
5876336 Swanson et al. Mar 1999 A
5885278 Fleischman Mar 1999 A
5913856 Chia et al. Jun 1999 A
5916213 Haissaguerre et al. Jun 1999 A
5957850 Marian et al. Sep 1999 A
6004269 Crowley et al. Dec 1999 A
6027500 Buckles et al. Feb 2000 A
6050267 Nardella et al. Apr 2000 A
6050994 Sherman Apr 2000 A
6059778 Sherman May 2000 A
6063078 Wittkampf May 2000 A
6064905 Webster, Jr. et al. May 2000 A
6068629 Haissaguerre et al. May 2000 A
6070094 Swanson et al. May 2000 A
6083170 Ben-Haim Jul 2000 A
6083222 Klein et al. Jul 2000 A
6099524 Lipson et al. Aug 2000 A
6101409 Swanson et al. Aug 2000 A
6116027 Smith et al. Sep 2000 A
6120476 Fung et al. Sep 2000 A
6165123 Thompson Dec 2000 A
6171305 Sherman Jan 2001 B1
6200314 Sherman Mar 2001 B1
6206831 Suorsa et al. Mar 2001 B1
6210337 Dunham et al. Apr 2001 B1
6216027 Willis et al. Apr 2001 B1
6224557 Ziel et al. May 2001 B1
6233491 Kordis et al. May 2001 B1
6241754 Swanson et al. Jun 2001 B1
6270493 Lalonde et al. Aug 2001 B1
6290697 Tu et al. Sep 2001 B1
6352534 Paddock et al. Mar 2002 B1
6395325 Hedge et al. May 2002 B1
6400981 Govari Jun 2002 B1
6423002 Hossack Jul 2002 B1
6475213 Whayne et al. Nov 2002 B1
6488678 Sherman Dec 2002 B2
6491710 Satake Dec 2002 B2
6508767 Burns et al. Jan 2003 B2
6508769 Bonnefous Jan 2003 B2
6508803 Horikawa et al. Jan 2003 B1
6516667 Broad et al. Feb 2003 B1
6517533 Swaminathan Feb 2003 B1
6517534 McGovern et al. Feb 2003 B1
6537271 Murray et al. Mar 2003 B1
6544175 Newman Apr 2003 B1
6546270 Goldin et al. Apr 2003 B1
6547788 Maguire et al. Apr 2003 B1
6569160 Goldin et al. May 2003 B1
6572547 Miller et al. Jun 2003 B2
6575966 Lane et al. Jun 2003 B2
6575969 Rittman et al. Jun 2003 B1
6579278 Bencini Jun 2003 B1
6582372 Poland Jun 2003 B2
6584345 Govari Jun 2003 B2
6589182 Loftman et al. Jul 2003 B1
6592525 Miller et al. Jul 2003 B2
6602242 Fung et al. Aug 2003 B1
6620103 Bruce et al. Sep 2003 B1
6632179 Wilson et al. Oct 2003 B2
6638222 Chandrasekaran et al. Oct 2003 B2
6640120 Swanson et al. Oct 2003 B1
6647281 Morency Nov 2003 B2
6656174 Hegde et al. Dec 2003 B1
6658279 Swanson et al. Dec 2003 B2
6663573 Goldin Dec 2003 B2
6666862 Jain et al. Dec 2003 B2
6676606 Simpson et al. Jan 2004 B2
6692441 Poland et al. Feb 2004 B1
6705992 Gatzke Mar 2004 B2
6709396 Flesch et al. Mar 2004 B2
6711429 Gilboa et al. Mar 2004 B1
6719756 Muntermann Apr 2004 B1
6735465 Panescu May 2004 B2
6736814 Manna et al. May 2004 B2
6743174 Ng et al. Jun 2004 B2
6773402 Govari et al. Aug 2004 B2
6776758 Peszynski et al. Aug 2004 B2
6796979 Lentz Sep 2004 B2
6796980 Hall Sep 2004 B2
6804545 Fuimaono et al. Oct 2004 B2
6811550 Holland et al. Nov 2004 B2
6824517 Salgo et al. Nov 2004 B2
6837884 Woloszko Jan 2005 B2
6845257 Fuimaono et al. Jan 2005 B2
6845264 Skladnev et al. Jan 2005 B1
6917834 Koblish et al. Jul 2005 B2
6922579 Taimisto et al. Jul 2005 B2
6923808 Taimisto Aug 2005 B2
6932811 Hooven et al. Aug 2005 B2
6945938 Grunwald Sep 2005 B2
6950689 Willis et al. Sep 2005 B1
6952615 Satake Oct 2005 B2
6958040 Oliver et al. Oct 2005 B2
7001383 Keidar Feb 2006 B2
7037264 Poland May 2006 B2
7047068 Haissaguerre May 2006 B2
7097643 Cornelius et al. Aug 2006 B2
7099711 Fuimaono et al. Aug 2006 B2
7105122 Karason Sep 2006 B2
7112198 Satake Sep 2006 B2
7115122 Swanson et al. Oct 2006 B1
7123951 Fuimaono et al. Oct 2006 B2
7131947 Demers Nov 2006 B2
7166075 Varghese et al. Jan 2007 B2
7181262 Fuimaono et al. Feb 2007 B2
7220233 Nita et al. May 2007 B2
7232433 Schlesinger et al. Jun 2007 B1
7247155 Hoey et al. Jul 2007 B2
7270634 Scampini et al. Sep 2007 B2
7288088 Swanson Oct 2007 B2
7291142 Eberl et al. Nov 2007 B2
7306561 Sathyanarayana Dec 2007 B2
7335052 D'Sa Feb 2008 B2
7347820 Bonnefous Mar 2008 B2
7347821 Dkyba et al. Mar 2008 B2
7347857 Anderson et al. Mar 2008 B2
7361144 Levrier et al. Apr 2008 B2
7422591 Phan Sep 2008 B2
7438714 Phan Oct 2008 B2
7455669 Swanson Nov 2008 B2
7488289 Suorsa et al. Feb 2009 B2
7507205 Borovsky et al. Mar 2009 B2
7519410 Taimisto et al. Apr 2009 B2
7529393 Peszynski et al. May 2009 B2
7534207 Shehada et al. May 2009 B2
7544164 Knowles et al. Jun 2009 B2
7549988 Eberl et al. Jun 2009 B2
7569052 Phan et al. Aug 2009 B2
7578791 Rafter Aug 2009 B2
7582083 Swanson Sep 2009 B2
7585310 Phan et al. Sep 2009 B2
7610073 Fuimaono et al. Oct 2009 B2
7648462 Jenkins et al. Jan 2010 B2
7697972 Verard et al. Apr 2010 B2
7704208 Thiele Apr 2010 B2
7720420 Kajita May 2010 B2
7727231 Swanson Jun 2010 B2
7736362 Eberl et al. Jun 2010 B2
7740629 Anderson et al. Jun 2010 B2
7758508 Thiele et al. Jul 2010 B1
7766833 Lee et al. Aug 2010 B2
7776033 Swanson Aug 2010 B2
7785324 Eberl Aug 2010 B2
7794398 Salgo Sep 2010 B2
7796789 Salgo et al. Sep 2010 B2
7799025 Wellman Sep 2010 B2
7815572 Loupas Oct 2010 B2
7819863 Eggers et al. Oct 2010 B2
7837624 Hossack et al. Nov 2010 B1
7859170 Knowles et al. Dec 2010 B2
7862561 Swanson et al. Jan 2011 B2
7862562 Eberl Jan 2011 B2
7879029 Jimenez Feb 2011 B2
7892228 Landis et al. Feb 2011 B2
7894871 Wittkampf et al. Feb 2011 B2
7918850 Govari et al. Apr 2011 B2
7957817 Gillespie et al. Jun 2011 B1
7996085 Levin Aug 2011 B2
8016822 Swanson Sep 2011 B2
8048028 Horn et al. Nov 2011 B2
8103327 Harlev et al. Jan 2012 B2
8128617 Bencini et al. Mar 2012 B2
8160690 Wilfley et al. Apr 2012 B2
8162935 Paul et al. Apr 2012 B2
8265745 Hauck et al. Sep 2012 B2
8267926 Paul et al. Sep 2012 B2
8290578 Schneider Oct 2012 B2
8317783 Cao et al. Nov 2012 B2
8369922 Paul et al. Feb 2013 B2
8400164 Osadchy et al. Mar 2013 B2
8403925 Miller et al. Mar 2013 B2
8406866 Deno et al. Mar 2013 B2
8414579 Kim et al. Apr 2013 B2
8449535 Deno et al. May 2013 B2
8454538 Wittkampf et al. Jun 2013 B2
8454589 Deno et al. Jun 2013 B2
8489184 Wilfley et al. Jul 2013 B2
8579889 Bencini Nov 2013 B2
8583215 Lichtenstein Nov 2013 B2
8603084 Fish et al. Dec 2013 B2
8603085 Jimenez Dec 2013 B2
8644950 Hauck Feb 2014 B2
8657814 Werneth et al. Feb 2014 B2
8672936 Thao et al. Mar 2014 B2
8679109 Paul et al. Mar 2014 B2
8728077 Paul et al. May 2014 B2
8740900 Kim et al. Jun 2014 B2
8755860 Paul et al. Jun 2014 B2
8771343 Weber et al. Jul 2014 B2
8876817 Avitall et al. Nov 2014 B2
8894643 Watson et al. Nov 2014 B2
8906011 Gelbart et al. Dec 2014 B2
8945015 Rankin et al. Feb 2015 B2
8998890 Paul et al. Apr 2015 B2
9089340 Hastings et al. Jul 2015 B2
9125565 Hauck Sep 2015 B2
9125668 Subramaniam et al. Sep 2015 B2
9168004 Gliner et al. Oct 2015 B2
9173586 Deno et al. Nov 2015 B2
9211156 Kim et al. Dec 2015 B2
9241687 McGee Jan 2016 B2
9241761 Rankin et al. Jan 2016 B2
9254163 Paul et al. Feb 2016 B2
9265434 Merschon et al. Feb 2016 B2
9271782 Paul et al. Mar 2016 B2
9283026 Paul et al. Mar 2016 B2
9370329 Tun et al. Jun 2016 B2
9393072 Kim et al. Jul 2016 B2
9463064 Subramaniam et al. Oct 2016 B2
20010029371 Kordis Oct 2001 A1
20020087208 Koblish et al. Jul 2002 A1
20020165448 Ben-Haim et al. Nov 2002 A1
20020198521 Maguire Dec 2002 A1
20030013958 Govari et al. Jan 2003 A1
20030088240 Saadat May 2003 A1
20030158548 Phan et al. Aug 2003 A1
20030158549 Swanson Aug 2003 A1
20030229286 Lenker Dec 2003 A1
20040006268 Gilboa et al. Jan 2004 A1
20040082860 Haissaguerre Apr 2004 A1
20040092806 Sagon et al. May 2004 A1
20040116793 Taimisto et al. Jun 2004 A1
20040147920 Keidar Jul 2004 A1
20040162556 Swanson Aug 2004 A1
20040186467 Swanson et al. Sep 2004 A1
20040210136 Varghese et al. Oct 2004 A1
20040215177 Swanson Oct 2004 A1
20040215186 Cornelius et al. Oct 2004 A1
20050033331 Burnett et al. Feb 2005 A1
20050059862 Phan Mar 2005 A1
20050059962 Phan et al. Mar 2005 A1
20050059963 Phan et al. Mar 2005 A1
20050059965 Eberl et al. Mar 2005 A1
20050065506 Phan Mar 2005 A1
20050065508 Johnson et al. Mar 2005 A1
20050070894 McClurken Mar 2005 A1
20050090817 Phan Apr 2005 A1
20050119545 Swanson Jun 2005 A1
20050119648 Swanson Jun 2005 A1
20050119649 Swanson Jun 2005 A1
20050119653 Swanson Jun 2005 A1
20050119654 Swanson et al. Jun 2005 A1
20050124881 Kanai et al. Jun 2005 A1
20050187544 Swanson et al. Aug 2005 A1
20050203597 Yamazaki et al. Sep 2005 A1
20050228286 Messerly et al. Oct 2005 A1
20050228504 Demarais Oct 2005 A1
20050273060 Levy et al. Dec 2005 A1
20060030919 Mrva et al. Feb 2006 A1
20060089634 Anderson et al. Apr 2006 A1
20060100522 Yuan et al. May 2006 A1
20060161146 Cornelius et al. Jul 2006 A1
20060247607 Cornelius et al. Nov 2006 A1
20060247683 Danek et al. Nov 2006 A1
20060253028 Lam et al. Nov 2006 A1
20060253116 Avitall et al. Nov 2006 A1
20070003811 Zerfass et al. Jan 2007 A1
20070016054 Yuan et al. Jan 2007 A1
20070016059 Morimoto et al. Jan 2007 A1
20070016228 Salas Jan 2007 A1
20070021744 Creighton Jan 2007 A1
20070049925 Phan et al. Mar 2007 A1
20070055225 Dodd, III et al. Mar 2007 A1
20070073135 Lee et al. Mar 2007 A1
20070088345 Larson et al. Apr 2007 A1
20070165916 Cloutier et al. Jul 2007 A1
20070167813 Lee et al. Jul 2007 A1
20070181139 Hauck Aug 2007 A1
20070225610 Mickley et al. Sep 2007 A1
20070238997 Camus Oct 2007 A1
20070270794 Anderson et al. Nov 2007 A1
20080009733 Saksena Jan 2008 A1
20080015568 Paul et al. Jan 2008 A1
20080025145 Peszynski et al. Jan 2008 A1
20080051841 Swerdlow et al. Feb 2008 A1
20080058836 Moll et al. Mar 2008 A1
20080086073 McDaniel Apr 2008 A1
20080091109 Abraham Apr 2008 A1
20080140065 Rioux et al. Jun 2008 A1
20080161705 Podmore et al. Jul 2008 A1
20080161795 Wang et al. Jul 2008 A1
20080161796 Cao et al. Jul 2008 A1
20080195089 Thiagalingam et al. Aug 2008 A1
20080228111 Nita Sep 2008 A1
20080243214 Koblish Oct 2008 A1
20080275428 Tegg et al. Nov 2008 A1
20080281322 Sherman et al. Nov 2008 A1
20080287803 Li et al. Nov 2008 A1
20080300454 Goto Dec 2008 A1
20080312521 Solomon Dec 2008 A1
20080312713 Wilfley et al. Dec 2008 A1
20090005771 Lieber et al. Jan 2009 A1
20090030312 Hadjicostis Jan 2009 A1
20090048591 Ibrahim et al. Feb 2009 A1
20090056344 Poch Mar 2009 A1
20090062790 Malchano et al. Mar 2009 A1
20090062795 Vakharia et al. Mar 2009 A1
20090076390 Lee et al. Mar 2009 A1
20090093810 Subramaniam et al. Apr 2009 A1
20090093811 Koblish et al. Apr 2009 A1
20090099472 Remmert et al. Apr 2009 A1
20090131932 Vakharia et al. May 2009 A1
20090163904 Miller et al. Jun 2009 A1
20090171341 Pope et al. Jul 2009 A1
20090171345 Miller et al. Jul 2009 A1
20090177069 Razavi Jul 2009 A1
20090177111 Miller et al. Jul 2009 A1
20090182316 Bencini Jul 2009 A1
20090209950 Starksen Aug 2009 A1
20090216125 Lenker Aug 2009 A1
20090240247 Rioux et al. Sep 2009 A1
20090259274 Simon et al. Oct 2009 A1
20090275827 Aiken et al. Nov 2009 A1
20090281541 Ibrahim et al. Nov 2009 A1
20090287202 Ingle et al. Nov 2009 A1
20090292209 Hadjicostis Nov 2009 A1
20090299355 Bencini et al. Dec 2009 A1
20090299360 Ormsby Dec 2009 A1
20090306643 Pappone et al. Dec 2009 A1
20100010487 Phan et al. Jan 2010 A1
20100057072 Roman et al. Mar 2010 A1
20100076402 Mazzone et al. Mar 2010 A1
20100094274 Narayan et al. Apr 2010 A1
20100106155 Anderson et al. Apr 2010 A1
20100113938 Park et al. May 2010 A1
20100145221 Brunnett et al. Jun 2010 A1
20100152728 Park et al. Jun 2010 A1
20100168557 Deno et al. Jul 2010 A1
20100168568 Sliwa Jul 2010 A1
20100168570 Sliwa et al. Jul 2010 A1
20100168831 Korivi et al. Jul 2010 A1
20100241117 Paul et al. Sep 2010 A1
20100249599 Hastings et al. Sep 2010 A1
20100249603 Hastings et al. Sep 2010 A1
20100249604 Hastings et al. Sep 2010 A1
20100298826 Leo et al. Nov 2010 A1
20100331658 Kim et al. Dec 2010 A1
20110028820 Lau et al. Feb 2011 A1
20110034915 Ibrahim et al. Feb 2011 A1
20110071400 Hastings et al. Mar 2011 A1
20110071401 Hastings et al. Mar 2011 A1
20110112569 Friedman et al. May 2011 A1
20110125143 Gross et al. May 2011 A1
20110130648 Beeckler et al. Jun 2011 A1
20110137153 Govari et al. Jun 2011 A1
20110144491 Sliwa et al. Jun 2011 A1
20110144524 Fish et al. Jun 2011 A1
20110160584 Paul et al. Jun 2011 A1
20110237933 Cohen Sep 2011 A1
20110282249 Tsoref et al. Nov 2011 A1
20110319782 Sweeney et al. Dec 2011 A1
20120004547 Harks et al. Jan 2012 A1
20120095347 Adam et al. Apr 2012 A1
20120101398 Ramanathan et al. Apr 2012 A1
20120116537 Liebetanz May 2012 A1
20120136346 Condie et al. May 2012 A1
20120136348 Condie et al. May 2012 A1
20120136351 Weekamp et al. May 2012 A1
20120172698 Hastings et al. Jul 2012 A1
20120172727 Hastings et al. Jul 2012 A1
20120172871 Hastings et al. Jul 2012 A1
20120238897 Wilfley et al. Sep 2012 A1
20120310064 McGee Dec 2012 A1
20120330304 Vegesna et al. Dec 2012 A1
20130023784 Schneider et al. Jan 2013 A1
20130023897 Wallace Jan 2013 A1
20130060245 Grunewald et al. Mar 2013 A1
20130066312 Subramaniam et al. Mar 2013 A1
20130066315 Subramaniam et al. Mar 2013 A1
20130079763 Heckel et al. Mar 2013 A1
20130165926 Mathur et al. Jun 2013 A1
20130172715 Just et al. Jul 2013 A1
20130172742 Rankin et al. Jul 2013 A1
20130172875 Govari et al. Jul 2013 A1
20130184706 Gelbart et al. Jul 2013 A1
20130190747 Koblish et al. Jul 2013 A1
20130197363 Rankin et al. Aug 2013 A1
20130226169 Miller et al. Aug 2013 A1
20130274582 Afonso et al. Oct 2013 A1
20130331739 Gertner Dec 2013 A1
20130345537 Thakur et al. Dec 2013 A1
20140012251 Himmelstein et al. Jan 2014 A1
20140058375 Koblish Feb 2014 A1
20140066764 Subramaniam et al. Mar 2014 A1
20140073893 Bencini Mar 2014 A1
20140075753 Haarer et al. Mar 2014 A1
20140081111 Tun et al. Mar 2014 A1
20140081112 Kim et al. Mar 2014 A1
20140081113 Cohen et al. Mar 2014 A1
20140081262 Koblish et al. Mar 2014 A1
20140100563 Govari et al. Apr 2014 A1
20140107453 Maskara et al. Apr 2014 A1
20140107636 Bencini Apr 2014 A1
20140128757 Banet et al. May 2014 A1
20140194867 Fish et al. Jul 2014 A1
20140200429 Spector et al. Jul 2014 A1
20140200430 Spector Jul 2014 A1
20140214028 Gelbart et al. Jul 2014 A1
20140228713 Thao et al. Aug 2014 A1
20140243917 Morley et al. Aug 2014 A1
20140261985 Selkee Sep 2014 A1
20140276052 Rankin et al. Sep 2014 A1
20140276811 Koblish et al. Sep 2014 A1
20140330150 Thakur et al. Nov 2014 A1
20140336518 Shuros et al. Nov 2014 A1
20140364715 Hauck Dec 2014 A1
20140364843 Paul et al. Dec 2014 A1
20140364848 Heimbecher et al. Dec 2014 A1
20150005624 Hauck et al. Jan 2015 A1
20150011995 Avitall et al. Jan 2015 A1
20150018813 Gliner Jan 2015 A1
20150133914 Koblish May 2015 A1
20150133920 Rankin et al. May 2015 A1
20150265341 Koblish Sep 2015 A1
20150265348 Avitall et al. Sep 2015 A1
20150342672 Bencini et al. Dec 2015 A1
20150374436 Subramaniam et al. Dec 2015 A1
20160008065 Gliner et al. Jan 2016 A1
20160100884 Fay et al. Apr 2016 A1
20160113712 Cheung et al. Apr 2016 A1
Foreign Referenced Citations (95)
Number Date Country
2682055 Oct 2008 CA
2847846 Mar 2013 CA
2848053 Mar 2013 CA
1269708 Oct 2000 CN
1455655 Nov 2003 CN
1942145 Apr 2007 CN
102271607 Dec 2011 CN
102573986 Jul 2012 CN
103917185 Jul 2014 CN
103987336 Aug 2014 CN
104619259 May 2015 CN
104640513 May 2015 CN
104661609 May 2015 CN
1343426 Sep 2003 EP
1343427 Sep 2003 EP
1502542 Feb 2005 EP
1547537 Jun 2005 EP
0985423 Apr 2006 EP
1717601 Nov 2006 EP
1935332 Jun 2008 EP
2755587 Jul 2014 EP
2755588 Jul 2014 EP
2136702 Jul 2015 EP
2897545 Jul 2015 EP
2000000242 Jan 2000 JP
200083918 Mar 2000 JP
2000504242 Apr 2000 JP
2002528039 Aug 2002 JP
2003504090 Feb 2003 JP
2004503335 Feb 2004 JP
2006239414 Sep 2006 JP
2007163559 Jun 2007 JP
2007244857 Sep 2007 JP
2009142653 Dec 2008 JP
2009518150 May 2009 JP
2010522623 Jul 2010 JP
2011142995 Jul 2011 JP
2011525842 Sep 2011 JP
2012531967 Dec 2012 JP
5336465 Nov 2013 JP
2014012174 Jan 2014 JP
2014531244 Nov 2014 JP
2015501162 Jan 2015 JP
2015509027 Mar 2015 JP
20100021401 Feb 2010 KR
101490374 Feb 2015 KR
WO9221278 Dec 1992 WO
WO9413358 Jun 1994 WO
WO9725916 Jul 1997 WO
WO9725917 Jul 1997 WO
WO9736541 Oct 1997 WO
9745156 Dec 1997 WO
WO9858681 Dec 1998 WO
9909879 Mar 1999 WO
WO9927862 Jun 1999 WO
WO0029062 May 2000 WO
WO0158372 Aug 2001 WO
WO0164145 Sep 2001 WO
WO0168173 Sep 2001 WO
WO0205868 Jan 2002 WO
WO0209599 Feb 2002 WO
WO0219934 Mar 2002 WO
WO0247569 Jun 2002 WO
WO02102234 Dec 2002 WO
WO03039338 May 2003 WO
WO2007079278 Jul 2007 WO
WO2008046031 Apr 2008 WO
WO2008118992 Oct 2008 WO
WO2009032421 Mar 2009 WO
2009043824 Apr 2009 WO
2009048943 Apr 2009 WO
2010054409 May 2010 WO
WO2010056771 May 2010 WO
2010082146 Jul 2010 WO
2011008444 Jan 2011 WO
2011033421 Mar 2011 WO
WO2011024133 Mar 2011 WO
WO2011089537 Jul 2011 WO
2011101778 Aug 2011 WO
WO2011095937 Aug 2011 WO
2012001595 Jan 2012 WO
WO2012001595 Jan 2012 WO
WO2012049621 Apr 2012 WO
WO2012066430 May 2012 WO
2012161880 Nov 2012 WO
WO2012151301 Nov 2012 WO
2012166239 Dec 2012 WO
2013040201 Mar 2013 WO
2013040297 Mar 2013 WO
2014036439 Mar 2014 WO
2014058375 Apr 2014 WO
2014072879 May 2014 WO
2014152575 Sep 2014 WO
2015143061 Sep 2015 WO
2015183635 Dec 2015 WO
Non-Patent Literature Citations (47)
Entry
International Preliminary Report on Patentability issued in PCT/US2015/021300 mailed Sep. 29, 2016, 7 pages.
International Search Report and Written Opinion issued in PCT/US2015/066874, mailed Apr. 1, 2016, 11 pages.
Extended European Search Report issued in EP Application No. 15174537.9, issued Mar. 2, 2016, 7 pages.
Goldberg, S. Nahum et al., “Variables Affecting Proper System Grounding for Radiofrequency Ablation in an Animal Model”, JVIR, vol. 11, No. 8, Sep. 2000, pp. 1069-1075.
Haverkamp, W., et. al. Coagulation of Ventricular Myocardium Using Radiofrequency Alternating Current: Bio-Physical Aspects and Experimental Findings, PACE, 12:187-195, Jan. 1989, Part II.
International Preliminary Examination Report issued in PCT/US2013/060612, completed Mar. 24, 2015, 10 pages.
International Preliminary Report on Patentability issued in PCT/US2008/058324, mailed Sep. 29, 2009, 9 pages.
International Preliminary Report on Patentability issued in PCT/US2012/055155, issued Mar. 18, 2014, 11 pages.
International Preliminary Report on Patentability issued in PCT/US2012/055309, issued on Mar. 18, 2014, 8 pages.
International Preliminary Report on Patentability issued in PCT/US2013/056211, completed Feb. 24, 2015, 5 pages.
International Preliminary Report on Patentability issued in PCT/US2013/058105, completed Mar. 10, 2015.
International Preliminary Report on Patentability issued in PCT/US2013/060194, mailed Mar. 24, 2015, 6 pages.
International Preliminary Report on Patentability issued in PCT/US2014/027491, mailed Sep. 24, 2015, 12 pages.
International Preliminary Report on Patentablity issued in PCT/US2013/060183, mailed Mar. 24, 2015, 6 pages.
International Search Report and Written Opinion issued in PCT/US2008/058324, dated Aug. 18, 2008, 11 pages.
International Search Report and Written Opinion issued in PCT/US2012/031819, mailed Sep. 27, 2012, 16 pages.
International Search Report and Written Opinion issued in PCT/US2012/055155, mailed Mar. 11, 2013, 19 pages.
International Search Report and Written Opinion issued in PCT/US2012/055309, mailed Nov. 19, 2012, 13 pages.
International Search Report and Written Opinion issued in PCT/US2012/072061, mailed Mar. 21, 2013, 9 pages.
International Search Report and Written Opinion issued in PCT/US2013/020503, mailed Mar. 20, 2013, 10 pages.
International Search Report and Written Opinion issued in PCT/US2013/021013, mailed Apr. 5, 2013, 14 pages.
International Search Report and Written Opinion issued in PCT/US2013/056211, mailed Jan. 20, 2014.
International Search Report and Written Opinion issued in PCT/US2013/058105, mailed Nov. 22, 2013, 16 pages.
International Search Report and Written Opinion issued in PCT/US2013/060183, mailed Jan. 27, 2014, 10 pages.
International Search Report and Written Opinion issued in PCT/US2013/060194, mailed Jan. 29, 2014.
International Search Report and Written Opinion issued in PCT/US2013/060194, mailed Jan. 29, 2014, 10 pages.
International Search Report and Written Opinion issued in PCT/US2013/060612, mailed Feb. 28, 2014, 16 pages.
International Search Report and Written Opinion issued in PCT/US2014/027491, mailed Sep. 23, 2014, 17 pages.
International Search Report and Written Opinion issued in PCT/US2015/021300, mailed Jun. 9, 2015, 11 pages.
International Search Report and Written Opinion issued in PCT/US2015/055173, mailed Jan. 18, 2016, 11 pages.
International Search Report and Written Opinion issued in PCT/US2015/057242, mailed Jan. 15, 2016, 11 pages.
International Search Report and Written Opinion issued in PCT/US2016/028006 mailed Jul. 12, 2016, 12 pages.
International Search Report and Written Opinion issued in PCTUS2015/031591, mailed Aug. 17, 2015, 11 pages.
Invitation to Pay Additional Fees and Partial International Search Report issued in PCT/US2014/027491, mailed Jul. 28, 2014, 5 pages.
Machi MD, Junji, “Prevention of Dispersive Pad Skin Burns During RFA by a Simple Method”, Editorial Comment, Surg Laparosc Endosc Percutan Tech, vol. 13, No. 6, Dec. 2003, pp. 372-373.
Neufeld, Gordon R. et al., “Electrical Impedance Properties of the Body and the Problem of Alternate-site Burns During Electrosurgery”, Medical Instrumentation, vol. 19, No. 2, Mar.-Apr. 1985, pp. 83-87.
Partial International Search Report issued in PCT/US2012/055155, mailed Dec. 20, 2012, 7 pages.
Patriciu, A. et al., “Detecting Skin Burns induced by Surface Electrodes”, published in Engineering in Medicine and Biology Society, 2001. Proceedings of the 23rd Annual International Conference of the IEEE, vol. 3, pp. 3129-3131.
Piorkolwski, Christopher et al., “First in Human Validation of Impedance-Based Catheter Tip-to-Tissue Contact Assessment in the Left Atrium”, Journal of Cardiovascular Electrophysiology, vol. 20, No. 12, Dec. 1, 2009, pp. 1366-1373.
Pires, L. A., et. al. Temperature-guided Radiofrequency Catheter Ablation of Closed-Chest Ventricular Myocardium with a Novel Thermistor-Tipped Catheter. American Heart Journal, 127(6):1614-1618, Jun. 1994.
Price, Adam et al., “Novel Ablation Catheter Technology that Improves Mapping Resolution and Monitoring of Lesion Maturation”, The Journal of Innovations in Cardiac Rhythm Management, vol. 3, 2002, pp. 599-609.
Price, Adam et al., “PO3-39 Pin Electrodes Improve Resolution: Enhanced Monitoring of Radiofrequency Lesions in the Voltage and Frequency Domains”, Heart Rhythm 2010, 31st Annual Scientific Sessions, May 12-15 in Denver Colorado.
Ring, E. R., et. al. Catheter Ablation of the Ventricular Septum with Radiofrequency Energy. American Heart Journal, 117(6)1233-1240, Jun. 1989.
Steinke, Karin et al., “Dispersive Pad Site burns Wth Modern Radiofrequency Ablation Equipment”, Surg Laparosc Endosc Percutan Tech, vol. 13, No. 6, Dec. 2003, pp. 366-371.
Zachary, J.M. et al., “PO4-86 Pin Electrodes Provide Enhanced Resolution Enabling Titration of Radiofrequency Duration to Lesion Maturation”, Heart Rhythm 2011, 32 Annual Scientific Sessions, May 4-7, San Francisco, CA.
Extended European Search Report issued in EP Application 16182627.6, mailed Nov. 8, 2016, 5 pages.
International Preliminary Report on Patentability issued in PCT/US2015/031591, mailed Dec. 6, 2016, 7 pages.
Related Publications (1)
Number Date Country
20160174865 A1 Jun 2016 US
Provisional Applications (1)
Number Date Country
62093771 Dec 2014 US